Brief: Oramed Gets U.S. Combination Therapy Patent For Oral GLP-1 & Insulin
04/01/2023 13:03
Jan 4 (Reuters) - Oramed Pharmaceuticals Inc ORMP.O :
* ORAMED GRANTED U.S. COMBINATION THERAPY PATENT FOR ORAL
GLP-1 &
INSULIN FOR THE TREATMENT OF DIABETES
* ORAMED PHARMACEUTICALS INC - PATENT SERVES AS AN EXTENSION
TO A
PATENT PREVIOUSLY GRANTED IN MAY 2022
Source text for Eikon: ID:nPnc8Xgcha
Further company coverage: ORMP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oramed Pharmaceuticals
See all newsBrief: Nano Dimension Appoints Nadav Kidron To Board Of Directors To Chair Strategy And Capital Allocation Committee
Oramed Pharmaceuticals Inc expected to post earnings of 43 cents a share - Earnings Preview
Brief: Oramed And Lifeward Announce Strategic Transaction
Brief: Oramed Receives $18 Million Payment From Scilex Holdings
Brief: Oramed Reports Fiscal Third Quarter 2025 Financial Results